Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


PHARMAC Agreement A Win-Win

PHARMAC is announcing an agreement that will result in two new drugs being fully funded – and at the same time save the taxpayer $1.9 million.

The contract with drug company Novartis means a long acting form of octreotide (brandname Sandostatin) and chlorthalidone (brandname Hygroton) will now be fully funded.

Octreotide is used for the treatment of a growth hormone condition. Chlorthalidone, which is a diuretic, is used for the treatment of high blood pressure and congestive heart failure.

The agreement also includes certainty over the availability of three other drugs. These are cyclosporin A (brandname Neoral), diclofenac (brandnames Flameril and Voltaren) and cyclopenthiazide (brandname Navidrex).

Cyclosporin A is an immuno suppressant used in the treatment of a variety of conditions including skin diseases, transplantations, and rheumatoid arthritis. Diclofenac is used to treat a number of inflammatory conditions including arthritis, while cyclopenthiazide is also a diuretic.

General Manager Wayne McNee says the announcement is good news for patients as they will have more choice and it also means they will continue to have access to these fully funded treatments.

“The decision will provide additional choices and benefits for patients. It really is a win-win for those patients needing these treatments and the taxpayer paying for them.”

Wayne McNee says the agreement is very timely as it comes when the pharmaceutical budget is stretched. Any savings will help the drug agency keep within budget.

“The reality is that the health budget isn’t infinite and we need to look very carefully at how it is spent. PHARMAC is committed to getting the best health outcomes it can from the funds available to meet the health needs of New Zealanders.”


© Scoop Media

Business Headlines | Sci-Tech Headlines


Voluntary Administration: Renaissance Brewing Up For Sale

Renaissance Brewing, the first local company to raise capital through equity crowdfunding, is up for sale after cash flow woes and product management issues led to the appointment of voluntary administrators. More>>


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>


Media Mega Merger: Full Steam Ahead For Appeal

New Zealand's two largest news publishers have confirmed they are committed to pursuing their appeal against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>


Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>